SARMs Powder Andarine / S4 CAS 401900-40-1 for Muscle Wasting Usage

SARMs Powder Andarine / S4 CAS 401900-40-1 for Muscle Wasting Usage

Andarine/S4
Product Name: S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide
Synonyms: S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide;N-[4-Nitro-3-(trifluoromethyl)phenyl]-(2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methylpropanamide;Ostarine;(2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide;MK-2866;Andarine;Propanamide,3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phe nyl]-,(2S)-;sarM s4
CAS:    401900-40-1
MF:    C19H18F3N3O6
MW:    441.36
Chemical Properties Pale Yellow Solid
Usage    It is a potent and tissue-selective androgen receptor modulator (SARM)

Andarine/S4 Description:

S4 (ANDARINE) is a SARM that was developed for treatment of muscle wasting, osteoporosis and benign prostatic hypertrophy. S4 is effective in not only maintaining lean body mass, but increasing it while reducing body fat.
 
The way that S4 works is by binding to the androgen receptor demonstrating bone and muscular anabolic activity. By binding to the androgen receptors, S4 alters the expression of genes and increases protein synthesis. This leads to the building of quality muscle. S4 can produce muscle growth as steroids do without the type of side effects that steroids produce.
Usage:
Andarine (GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.

Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.

This suggests that it is able to competitively block binding to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.